The Company

A Legacy of Innovation

UC Berkeley professors and award-winning physicists at Lawrence Berkeley National Laboratory, Marvin L. Cohen and Alex Zettl founded Nanōmix in 2000 as a Berkeley Lab spinout to commercialize their proprietary nanotechnology for detecting a wide variety of biological molecules and gases for disease management, industrial process control, and the detection of pollutants in air and water. With private funding from its lead investor Alta Partners (San Francisco) and others, as well as public funding from the U.S. Small Business Administration Innovation Research Program and the Department of Homeland Security, Nanōmix soon achieved a succession of major milestones — including the first large-scale integration of nanotube electronics on a four-inch silicon wafer that forms the basis for the company’s universal detection platform. In 2009, Nanōmix was relaunched and shifted focus to adapting its proprietary carbon nanotube sensor technology to the in vitro diagnostics market. Today, Nanōmix is poised to become the premier provider of analytical detection devices for the next generation of rapid point-of-care (POC) diagnostics in the projected $18 billion global POC market (2012). Based at its 13,000 sq.ft. research and fabrication facility in Emeryville, California, the company is developing Omega-3, a fully integrated POC solution for critical care testing and is ready for partnering opportunities under its collaborative business model. The initial product is for the diagnosis of myocardial infarction by first responders and in emergency rooms.

Partnering with industry leaders for product development and distribution